Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited treatment options for advanced or unresectable disease.
• Conventional chemotherapy offers minimal benefit, and while sorafenib improves survival, alternatives are scarce for patients intolerant or progressing on this therapy.
• The cellular-mesenchymal-epithelial transition (c-MET) factor receptor is a promising molecular target in HCC, with ongoing research into its inhibitors.

Purpose of the Study:

• To review the c-MET/hepatocyte growth factor (HGF) signaling pathway and its role in HCC.
• To discuss preclinical and clinical trial data for c-MET inhibitors in HCC treatment.
• To highlight emerging therapeutic strategies targeting the c-MET pathway for HCC.

Main Methods:

• Literature review of preclinical studies on c-MET inhibitors in HCC.
• Analysis of clinical trial data (Phase II and III) for tivantinib and cabozantinib in HCC.
• Description of the c-MET/HGF signaling pathway and its implications in HCC pathogenesis.

Main Results:

• The c-MET/HGF pathway is implicated in HCC development and progression.
• Phase II trials of c-MET inhibitors like tivantinib and cabozantinib have shown encouraging results.
• These promising findings have advanced c-MET inhibitors into Phase III clinical trials for HCC.

Conclusions:

• Inhibitors targeting the c-MET/HGF pathway represent a promising therapeutic strategy for HCC.
• Further clinical evaluation is crucial to establish the efficacy and safety of these agents.
• Targeting molecular pathways like c-MET/HGF offers a new direction for advanced HCC treatment.